Swiss National Bank Sells 32,300 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Swiss National Bank lowered its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 5.6% during the 4th quarter, HoldingsChannel reports. The fund owned 543,860 shares of the company’s stock after selling 32,300 shares during the period. Swiss National Bank’s holdings in Bausch Health Companies were worth $4,394,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. XTX Topco Ltd purchased a new position in Bausch Health Companies in the third quarter worth about $938,000. SG Americas Securities LLC increased its position in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after acquiring an additional 1,263,706 shares in the last quarter. Range Financial Group LLC purchased a new position in Bausch Health Companies in the 4th quarter worth approximately $1,004,000. Geode Capital Management LLC lifted its position in Bausch Health Companies by 20.5% in the 3rd quarter. Geode Capital Management LLC now owns 636,082 shares of the company’s stock valued at $6,448,000 after acquiring an additional 108,269 shares in the last quarter. Finally, Goldentree Asset Management LP boosted its stake in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after purchasing an additional 6,958,717 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

BHC stock opened at $7.03 on Wednesday. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -58.58, a P/E/G ratio of 0.37 and a beta of 0.59. The business’s 50-day moving average is $7.12 and its two-hundred day moving average is $7.72. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BHC shares. Royal Bank of Canada decreased their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research note on Thursday, January 30th. Jefferies Financial Group reissued a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bausch Health Companies has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.